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1. INTRODUCTION 
 Options for the surgical treatment of cardiovascular diseases include 
implantable cardiovascular devices such as stents, the total artificial heart, vascular 
grafts, heart valves, and ventricular assist devices. Still, cardiovascular devices 
implanted in the human body have been shown to bee associated with complications 
indicating the need of improving their biocompatibility. Biocompatibility has been 
defined as "the ability of a material to perform with an appropriate host response in 
a specific application” (1). Cardiovascular devices, such as the left ventricular assist 
device, have been shown to be associated with thromboembolism, bleeding, and 
infection, which are characteristics of poor biocompatibility (2). Activation of the 
coagulation cascade caused by the artificial surfaces of such cardiovascular devices 
has been shown to cause thromboembolic events (3).  
 To improve the biocompatibility of implantable cardiovascular devices 
whose artificial surfaces will be contacting the blood stream, endothelial cells might 
be an optimal lining since they naturally occur in human blood vessels at the blood-
contacting surface. Endothelial cells secrete--among others factors--chemotactic, 
growth, and nonthrombogenic factors such as prostacyclin and nitric oxide (NO).  
Bordenave et al. suggested the seeding of endothelial cells onto vascular 
grafts because this metabolically active endothelial lining plays a major role in 
preventing in vivo blood thrombosis and because vascular grafts implanted into 
humans do not form an endothelial monolayer spontaneously (4).  
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Nikolaychik et al. have tested endothelial cell monolayers under dynamic conditions 
inside a beating ventricular prosthesis in vitro with the goal of producing a 
permanent biocompatible artificial cardiac prosthesis (5). They have measured an 
endothelial cell loss of 35% indicating denudation of the endothelial cell lining.  
Scott-Burden et al., investigated smooth muscle cells genetically engineered 
with endothelial-Nitric Oxides Synthase seeded on the surfaces of left ventricular 
assist devices and implanted in a calf for 24 hours (6). Genetically engineered 
smooth muscle cells have been shown to secrete Nitric Oxide and to provide an 
adherent, nonthrombogenic autologous cell lining.  
There are drawbacks, however, to using either endothelial cells or smooth 
muscle cells to line cardiovascular devices. Neither cell type is abundantly available 
nor easily accessible, harvested, and isolated. Moreover, endothelial cells have been 
observed to slough off easily from artificial surfaces (2). The process of harvesting, 
isolating, and cultivating both endothelial cells and smooth muscle cells from 
autologous vessels is invasive and time-consuming.  
In contrast, auricular chondrocytes are abundant, readily accessible, and able 
to be easily and efficiently harvested. One potential source of chondroctyes, 
auricular cartilage, can be harvested by a minimally invasive technique that 
preserves cell viability, decreases surgical time, and postoperative complications (7). 
In vivo, chondrocytes are naturally nourished by diffusion and produce substantial 
amounts of extracellular matrix components (8). Therefore, cultured chondrocytes 
may be more likely to remain viable and adherent to artificial surfaces. 
  
 
 
Page 7 of 32 
Doreen Rosenstrauch 
Use of Autologous Auricular Chondrocytes For Lining Left Ventricular Assist Devices 
 We investigated in vitro the isolation and culture of auricular cartilage as a 
more efficient, less invasive means of obtaining autologous tissue for lining the 
luminal surfaces of implantable left ventricular assist devices (LVAD’s) and in vivo 
the adherence of cultured auricular cartilage cells (chondrocytes) to the luminal 
surfaces of a LVAD in a calf model. 
 
2. MATERIALS AND METHODS  
2.1. In Vitro Experiments 
2.1.1.   Tissue Harvesting 
   Six weeks before the in vivo experiments began, a 2-mm-
diameter tissue sample was harvested from the ear of a 4-month-old longhorn-
crossbreed calf weighing 70 kg (4B Livestock, Midway, Texas) by punch biopsy 
with a trephine (Nasco, Fort Atkinson, WI) (Figure 1). The biopsy was performed 
under sterile conditions and local anesthesia. The tissue sample was immediately 
placed in sterile cell culture medium containing antibiotics (Table 1) and transferred 
to a sterile hood. The sample was kept at 4ºC for a minimal amount of time to keep 
the tissue viable. 
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FIGURE 1 Harvest of bovine auricular cartilage from the ear of the tissue-donor 
calf. (Left) A 2-mm-diameter biopsy sample (arrow) of auricular cartilage being 
held by a pickup. The trephine used to obtain the sample is shown still in the ear. 
(Right) Biopsy site (arrow) at the ear after the trephine was removed.  
 
2.1.2.   Tissue Isolation 
   Under the sterile hood, auricular elastic cartilage was removed 
from the surrounding dermal tissue of the biopsy sample by microdissection. The 
isolated cartilage was placed in 10- x 10-mm tissue culture dishes with 2% 
antimycotic-antibiotic phosphate-buffered saline (Table 2) and incubated at 37ºC for 
10 minutes. Multiple small pieces of the cartilage were placed in 6-well tissue 
culture plates in 500 µl of modified RPMI cell culture medium and incubated at 
37ºC. 
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Table 1. Composition of Modified RPMI 1640 Cell Culture Medium 
RPMI 1640 medium (90%) 
Fetal bovine serum (10%)* 
Sodium pyruvate (1X) † 
Minimum essential amino acids (500 µl) 
L-Glutamine (2mmol/L) 
Penicillin G  
Streptomycin  
HEPES (1X) 
*Equitech-Bio, Inc., Kerrville, TX.  
†100 mM MEM sodium pyruvate solution; GIBCO-BRL, Rockville, MD.  
‡Sigma, St. Louis, MO. 
 
Table 2. Composition of 2% Antimycotic-Antibiotic Phosphate-Buffered Saline  
 Solution 
Dulbecco’s phospate-buffered saline (1X)* 
Penicillin G sodium (10,000 U/ml) 
Streptomycin sulfate (10,000 µg/ml) 
Amphotericin B (25 µg/ml) 
*Sigma, St. Louis, MO. 
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2.1.3.   Cell Culture 
   Chondrocytes growing from the auricular cartilage were 
cultured under sterile conditions and maintained in a humidified 5% CO2 incubator 
at 37ºC. Every 12 hours, drops of medium were added to each culture well. After 5-
7 days, when chondrocytes became adherent to the culture dishes, cartilage pieces 
were removed.  The chondrocytes were then passaged as follows. First, they were 
trypsinized in a solution of 0.5 g trypsin and 0.2 g EDTA (Sigma, St. Louis, MO). 
Then, when the cells became detached, fetal bovine serum was added to inactivate 
the trypsin. The resulting single cell suspension was then transferred to tissue culture 
plates to establish a monolayer of chondrocytes. Thereafter, the cell culture medium 
was changed every 48 hours. Chondrocytes were passaged twice, and cells of the 
second passage were used for subsequent experiments.  
 
2.1.4.   Histology 
   Fine (1-µm-thick), paraffin-embedded sections of pure elastic 
cartilage tissue were stained with Verhoff-van Gieson stain to visualize elastic 
fibers, Masson’s trichrome stain to visualize collagen fibers, and hematoxylin and 
eosin to assess tissue and cell morphology. 
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2.1.5.   Immunocytochemistry 
   A portion of the second-passage chondrocytes from each 
culture plate was plated on slides and fixed in 1% formalin for 
immunocytochemistry using a double-antibody labeling technique. Paraffin-
embedded sections of pure elastic cartilage tissue immunostained in the same way 
served as a control. The primary antibody used was collagen type II (NCL-Coll-Iip; 
Novocastra); the secondary antibody used was a biotinylated immunoglobulin 
specific for the primary antibody (Vectastain® Elite IgG; Vector Laboratories, 
Burlington, CA). In brief, deparaffinized and hydrated cartilage tissue sections and 
cells were incubated in 3% hydrogen peroxide for 10 minutes to quench endogenous 
peroxidase activity. All specimens were then incubated with normal mouse serum 
for 20 minutes to block nonspecific binding sites. Next, all specimens were exposed 
to a 1:50 diluted solution of the primary antibody for 1 hour. After repeated washes, 
all specimens were incubated with the secondary antibody for 30 minutes. Next, all 
specimens were exposed to avidin DH and biotinylated enzyme (Vectastain® Elite 
ABC reagent) for 30 minutes and then to diaminobenzidine as a peroxidase substrate 
for 30 seconds. Finally, all specimens were counterstained with hematoxylin for 1 
minute. Control incubations were performed in the absence of the primary antibody. 
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2.1.6.   Cell Seeding 
Four implantable pneumatic LVAD’s (HeartMate; Thermo 
Cardiosystems, Inc., Woburn, MA) were used for the in vitro cell seeding 
experiments. The HeartMate has two luminal artificial surfaces: a flexible 
diaphragm made of a “biomer” (i.e., polyurethane flocked with polyester 
microfibrils) and a metal housing made of sintered titanium microspheres6 .One of 
the four LVAD’s used in the in vitro experiments was later used in the in vivo 
experiments described below. 
Seven days before the in vivo experiments began, each of the four LVAD’s 
was seeded with a total of 3 x 107 autologous cells under sterile conditions. The inlet 
and outlet conduits of each LVAD were closed, and the LVAD was placed in a 
humidified 5% CO2 incubator at 37ºC. Each LVAD was tilted 15 degrees every 2 
hours for 24 hours during cell seeding to ensure complete cell coverage of surfaces. 
After seeding was completed, three samples of cell culture medium were collected 
from each LVAD and assessed for the number of nonadherent cells using a Coulter 
counter (Coulter, Hialeah, FL). The seeding procedure and the consecutive 
assessment of seeding efficiency were repeated to ensure complete cell coverage of 
both luminal surfaces of the LVAD. Each LVAD was then incubated for 4 days in 
the same incubator. Cell culture medium supplemented with 50 µg/ml of sodium 
ascorbate (Sigma, St. Louis, MO) was changed every 48 hours to promote 
extracellular matrix synthesis in order to maximize the adherence of cells to both 
artificial surfaces. After each medium change, samples were collected to assess the 
  
 
 
Page 13 of 32 
Doreen Rosenstrauch 
Use of Autologous Auricular Chondrocytes For Lining Left Ventricular Assist Devices 
number of nonadherent cells as before and to calculate seeding efficiency based on 
the number of initially seeded cells. 
 
2.1.7.   Cell Preconditioning 
Because preconditioning a.) Promotes good cell adherence 
once an LVAD is implanted and perfusion initiated and b.) Cell loss reaches a 
plateau after 12 hours of preconditioning, each seeded LVAD was subjected to an in 
vitro preconditioning regimen for 12 hours that exposed the cell lining to flow 
conditions(9). In brief, 12 hours before the in vivo experiments began, each LVAD 
was incorporated under sterile conditions into an in vitro flow loop (Figure 2). The 
in vitro flow loop was connected to a pneumatic drive console operated at 70 beats 
per minute and an ejection fraction of 30%. It has been demonstrated that cell loss 
reached a plateau after 12 hours of preconditioning a smooth muscle cell layer on 
LVAD surfaces (9). During the 12-hour preconditioning period, 18 samples of cell 
culture medium were collected (three each at 0, 0.3, 3, 5, 7 and 9 hours) to assess the 
amount of cell loss and to calculate preconditioning efficiency based on the number 
of initially seeded cells. 
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FIGURE 2 In vitro flow loop used for preconditioning of seeded cells. The loop 
consisted of a reservoir filled with cell culture medium (1) and the cell-seeded 
LVAD (2). Samples of cell culture medium emptied into the reservoir via a stop 
cock (3) were collected from the reservoir at several time points during the 12-hour 
preconditioning period as described in Materials and Methods. The in vitro flow 
loop was connected to a pneumatic drive console (not shown). 
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2.2. In Vivo Experiments 
2.2.1.   Animal Care 
   The tissue- donor calf used in the in vivo experiments 
received humane care in compliance with the Principles of Laboratory Animal Care 
prepared by the National Society for Medical Research and the Guide for the Care 
and Use of Laboratory Animals prepared by the Institute of Laboratory Animal 
Resources and published by the National Institutes of Health (NIH Publication No. 
86-23, revised 1985). 
 
2.2.2.   LVAD Preparation 
   Immediately before implantation, one of the four seeded 
LVAD’s used in the in vitro experiments was disconnected from its preconditioning 
in vitro flow loop and discharged of cell culture medium. To eliminate any 
remaining cell culture medium, the LVAD was rinsed twice with pure RPMI 
medium and washed three times with 37ºC phosphate-buffered saline. Once the 
LVAD was filled with PBS, its inflow and outflow conduits were capped and its 
external surface sterilized by rinsing twice with 70% ethanol. The LVAD was then 
transported under sterile conditions to the operating room for immediate 
implantation. 
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2.2.3.   LVAD Implantation 
2.2.3.1.   Operative Procedure. Once prepared, the seeded 
LVAD was implanted into the tissue-donor calf under cardiopulmonary bypass 
using a standard procedure described previously (10). In brief, an abdominal incision 
was made through which the LVAD was placed. The LVAD’s percutaneous 
driveline was tunneled subcutaneously and exteriorized high on the left flank. The 
inflow and outflow conduits were passed through separate 1- to 2-cm-long incisions 
in the anterior left hemidiaphragm. A 20-mm-diameter low-porosity Dacron outlet 
graft was preclotted using autologous serum and blood and then anastomosed end-
to-side at the descending thoracic aorta. The sewing ring of the LVAD was sutured 
to the left ventricular apex, using interrupted #2-0 braided polyester sutures with 
Teflon felt pledgets. A small crux incision was made in the apex, and a coring knife 
was inserted into the left ventricular cavity.  A full-thickness circular segment of the 
apical myocardium was then excised. The pump inlet tube was inserted into the left 
ventricle. Air was removed from the LVAD via a needle inserted into the Dacron 
graft. Protamine sulfate was administered intravenously to antagonize heparin. The 
LVAD was kept in automatic mode at all times while implanted. 
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2.2.3.1.   Postoperative Care. Dextrose 5% in Ringer’s lactate 
solution was infused intravenously as necessary to maintain central venous pressure 
(CVP). Potassium chloride was added to the intravenous infusion as indicated by 
serial measurements of serum potassium. Sodium cefonicid 1 g was administered 
daily for 4 days to prevent infection. Butorphanol 10 mg was given i.m. every 4-8 
hours for pain. No anticoagulative therapy was administered. 
 
2.2.4.   Necropsy and Gross Observations 
   Seven days after LVAD implantation, the calf was euthanized 
(by i.v. administration of 3 mg/kg heparin and then 1 ml/kg beuthanasia-D) and 
necropsied. The LVAD and pertinent organs (e.g., heart, lungs, liver, rumen, spleen, 
kidney, adrenal glands, and brain) were examined grossly and photographed. The 
organs were evaluated for the presence of emboli, ischemia, and infarction.  
 
 
 
 
 
 
  
 
 
Page 18 of 32 
Doreen Rosenstrauch 
Use of Autologous Auricular Chondrocytes For Lining Left Ventricular Assist Devices 
2.2.5. Scanning Electron Microscopy and Transmission Electron  
   Microscopy 
   The LVAD was disassembled, inspected, photographed, and 
subjected to scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM). In brief, both artificial surfaces of the LVAD’s, along with the 
attached cellular lining, were immediately fixed in Millonig’s phosphate buffer 
supplemented with 3% glutaraldehyde and incubated for several days at 4ºC. SEM 
samples were further fixed in 1% osmium tetroxide for 1 hour at room temperature. 
The samples were then rinsed with Millonig’s phosphate buffer and gradually 
dehydrated with ethanol (9). 
 For SEM, samples of the diaphragm and the titanium housing of the LVAD 
were coated with gold using a Denton Vacuum 502A Cold Sputter Module. The 
samples were then placed in a digital scanning electron microscope (Zeiss Model 
960) to visualize the cell-lined sintered titanium and textured polyurethane surfaces.  
 For TEM, samples of the LVAD’s diaphragm and housing were infiltrated 
with resin and ethanol, embedded in the resin overnight, cut with a diamond knife to 
a thickness of 60-80 nm, pulse-stained in uranyl acetate and lead citrate, and finally 
viewed under a transmission electron microscope (JEOL Model 1200EX). 
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3. RESULTS  
3.1.  In Vitro Experiments 
3.1.1.   Histology 
   Isolated auricular cartilage tissue stained positive for elastic 
and collagen fibers, indicating the presence of pure elastic cartilage. Tissue culture 
cells derived from isolated auricular cartilage tissue at zero passage stained positive 
for elastic and collagen fibers, indicating the presence of chondrocytes (Figure 3). 
 
FIGURE 3 Chondrocytes (Cc) growing from a piece of elastic cartilage (Ec) at zero 
passage. Tissue culture cells (Cc) derived from isolated auricular cartilage tissue 
(Ec) at zero passage stained positive for elastic and collagen fibers, indicating the 
presence of chondrocytes. 
Cc 
Ec 
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3.1.2.   Immunocytochemistry 
   Elastic cartilage tissue and cells at second passage stained 
positive for collagen II, indicating the presence of chondrocytes (Figure 4). Cells 
treated with cell culture medium supplemented with sodium ascorbate showed much 
stronger staining of collagen II, indicating improved collagen synthesis. 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 Immunocytochemistry of elastic cartilage (left) and chondrocytes in 
tissue culture of second passage (right). Positive staining for collagen II indicated 
the presence of chondrocytes. 
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3.1.3.   Seeding Efficiency 
   The luminal surfaces of the four LVAD’s, consisting of 
sintered titanium and polyurethane, were seeded twice with autologous auricular 
chondrocytes during the first seeding procedure and the second seeding procedure. 
The first seeding efficiency was 92.66 ± 10.08% and the second seeding efficiency 
was 98.14 ± 0.93%.The calculated total seeding efficiency was 95.11% ± 4.23% (n 
= 4) (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 Seeding efficiency. The first seeding efficiency of four LVAD’s was 
92.66 ± 10.08% and the second seeding efficiency of four LVAD’s was 98.14 ± 
0.93%. Total seeding efficiency of four LVAD’s was 95.11 ± 4.23%. 
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3.1.4.   Cumulative Cell Loss During Preconditioning 
   During the 12 hours of preconditioning under flow conditions 
in vitro, the average cumulative cell loss was 11.45± 0.21% (n = 4). The average 
cumulative cell loss was 2.22± 0.32% after 30 minutes, 5.13± 0.15% after 3 hours, 
7.47± 0.20% after 5 hours, and 9.78± 0.35% after 7 hours (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 Cumulative cell loss (n = 4). The cumulative cell loss during 
preconditioning under flow conditions on the in vitro flow loop was 2.22 ± 0.32% 
after 30 minutes, 5.13 ± 0.15% after 3 hours, 7.47 ± 0.20% after 5 hours, 9.78 ± 
0.35% after 7 hours and 11.45 ± 0.21 after 9 hours. 
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3.2.  In Vivo Experiments 
3.2.1.   Necropsy and Gross Observations 
   Gross examination of the luminal surfaces of the LVAD 
revealed an intact cell layer and complete coverage of both artificial surfaces after 7 
days of implantation (Figure 7). There was no evidence of infection or thrombus on 
either luminal surface, within the graft, or within the aortic anastomoses. Lungs, 
liver, rumen, spleen, kidney, rete mirabile, adrenal glands, and brain showed no 
gross and no histological evidence of emboli, ischemia, or infarction.  
 
 
 
 
 
 
 
FIGURE 7 Gross appearance of the implanted LVAD’s biomaterial surfaces after 7 
days of implantation in vivo. (Left) Textured polyurethane surface; (right) sintered 
titanium surface. The luminal surfaces of the LVAD are completely covered with an 
intact cell layer. 
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3.2.2.   SEM and TEM 
   SEM revealed an extensive amount of extracellular matrix 
components and an intact, well-incorporated cellular lining on the sintered titanium 
and polyurethane surfaces of the implanted LVAD (Figure 8). TEM revealed a well-
established monolayer of chondrocytes (Figure 9). No endothelial cells were seen. 
 
 
 
 
 
 
 
 
FIGURE 8 Scanning electron microscopy of the implanted LVAD’s biomaterial 
surfaces after 7 days of implantation in vivo. An extensive amount of extracellular 
matrix and an intact, well-incorporated cellular coating (arrows) were noted on the 
textured polyurethane (left) and sintered titanium (right) surfaces of the implanted 
LVAD. 
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FIGURE 9 Transmission electron microscopy of the implanted LVAD’s biomaterial 
surfaces after 7 days of implantation in vivo. (Left) Textured polyurethane surface; 
(right) sintered titanium surface. A well-established monolayer of chondrocytes was 
revealed. No endothelial cells were seen. 
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4. DISCUSSION  
 This study demonstrates the feasibility of using autologous chondrocytes 
derived from auricular elastic cartilage to line the luminal surfaces of LVAD’s.  
Auricular elastic cartilage is an accessible source of autologous cells. Chondrocytes 
can be harvested from the ear under local anesthesia, and they can be isolated more 
efficiently than vascular smooth muscle or endothelial cells. The isolation of 
chondrocytes from cartilage described here is simple, fast and easy. Moreover, 
chondrocytes derived from auricular cartilage can adhere strongly to artificial 
surfaces because of their ability to manufacture collagen II, elastin and other 
important constituents of the extracellular matrix. Hypothetically, cardiovascular 
assist devices lined with auricular chondrocytes might also allow easier recruitment 
of circulating endothelial cells and thus improve the process known as fallout 
healing (11). 
 Support for this idea has come from development of the HeartMate® LVAD. 
Even in early calf studies, the HeartMate®’s artificial surfaces encouraged the 
immediate deposition of a stable, uniform, antithrombogenic, nonhemolytic 
neointimal lining (12). Later, in human studies, endothelial cells were found on 
samples taken from the luminal surfaces of LVAD’s after implantation (13). 
Presumably, blood-borne endothelial cells or endothelial cell precursors had been 
deposited on the blood-contacting surfaces, which may explain in large part the low 
reported incidence of thrombogenicity and clinical thromboembolic problems 
associated with the use of LVAD’s. Another study showed endothelial cells to have 
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high affinity for heparinized surfaces in addition to cell surface receptors involved in 
adhesion to collagen (14); this suggested that a lining of autologous chondrocytes 
strongly adherent to artificial surfaces might provide an ideal attachment zone for 
endothelial cells. Yet another study showed that genetically engineered smooth 
muscle cells lining the luminal surface of the HeartMate® were nonthrombogenic 
(9) suggesting that the use of such cells might improve the hemocompatibility of 
artificial surfaces. 
 Beyond the immediate scope of our study, our findings also have some 
implications for the use of auricular cartilage in tissue engineering. Other 
investigators have successfully used a mixed-cell population of vascular cells from 
ovine carotid arteries to create a heart valve on a scaffold of biodegradable porous 
polyhydroxyalkanoate (15). Still, the ideal cell source for tissue-engineering a heart 
valve seem to remain a mystery (15). 
 In conclusion, auricular elastic cartilage is an accessible source of autologous 
tissue. Chondrocytes derived from such cartilage can be efficiently harvested, 
isolated, cultured and seeded and can adhere very strongly to artificial surfaces 
because of their ability to produce collagen II, elastin and other important 
constituents of extracellular matrix. Therefore, auricular chondrocytes are a potential 
source of autologous cells for lining large cardiovascular assist devices such as 
LVAD’s and improving their long-term biocompatibility.  Our successful short-term 
feasibility study in which auricular chondrocytes were used to line the luminal 
surfaces of a LVAD in a calf model warrants further study in vivo. 
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5. ABSTRACT  
 Background: Auricular elastic cartilage is a potential source of autologous 
cells for lining the luminal surfaces of left ventricular assist devices (LVAD’s) to 
improve long-term biocompatibility. We evaluated this potential in vitro and in vivo 
in a calf model.  
Methods: In vitro, auricular cartilage was harvested from the anesthetized ear of a 
calf, isolated, and cultured on tissue culture dishes. Primary chondrocytes were 
typed by immunocytochemistry, transferred into culture media, passaged twice, and 
seeded onto the blood-contacting luminal surfaces of four LVAD’s (HeartMate; 
Thermo Cardiosystems, Inc., Woburn, MA). The seeded cell linings were 
preconditioned under flow conditions in vitro to promote cell adhesion to the 
luminal surfaces. Seeding efficiency and cumulative cell loss under flow conditions 
in vitro were quantitated.  In vivo, one of the four preconditioned, autologous 
chondrocyte-lined LVAD’s was implanted into the tissue-donor calf; run for 7 days; 
explanted; and finally evaluated grossly, by scanning electron microscopy, and by 
transmission electron microscopy. 
Results: Autologous chondrocytes were seeded onto the luminal surfaces of the four 
LVAD’s.  The seeding efficiency was 95.11± 4.23% (n = 4). Cumulative cell loss 
during preconditioning under flow conditions in vitro did not exceed 12% (n = 4).  
After 7 days of in vivo implantation, the luminal surfaces of the implanted LVAD 
demonstrated an intact, strongly adherent cellular lining.  There was no evidence of 
thromboembolic events at necropsy. 
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Conclusions: Auricular elastic cartilage is a ready and easily accessible source of 
chondrocytes whose ability to produce collagen II and other important extracellular 
matrix constituents allows them to adhere strongly to the luminal surfaces of 
LVAD’s.  The simple method of isolating and expanding auricular chondrocytes 
presented here could be used to provide autologous cell linings for LVAD’s and 
other cardiovascular devices to improve their long-term biocompatibility.  Our 
successful short-term feasibility study in a calf model warrants further study in vivo.  
 
Key words: auricular chondrocytes, tissue engineering, left ventricular assist device, 
elastic cartilage 
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